Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia

Paul Bird¹, Geoffrey Littlejohn²,³, Belinda Butcher¹,⁴, Tegan Smith², Catherine O’Sullivan², David Witcombe⁵ & Hedley Griffiths²,⁶

1. University of New South Wales, Kensington, New South Wales, Australia
2. OPAL Rheumatology Ltd, Sydney, New South Wales, Australia
3. Monash University, Clayton, Victoria, Australia
4. WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia
5. Pfizer Australia, Sydney, New South Wales, Australia
6. Barwon Rheumatology Service, Geelong, Victoria, Australia

Corresponding Author:
Name: Catherine O’Sullivan
Email: cath.osullivan@opalrheumatology.com.au

Online Resource 3. Monotherapy and combination therapy treatment patterns at treatment initiation and at 74 to 104 weeks follow-up in the monotherapy and combination therapy overall populations.

|                         | Monotherapy (overall population) | Combination therapy (overall population) |
|-------------------------|----------------------------------|------------------------------------------|
|                         | Index                             | 74 to < 104 weeks follow-up              | Index                                      | 74 to < 104 weeks follow-up |
|                         | bDMARD (N = 720) n (%)            | TOF (N = 282) n (%)                      | bDMARD (N = 463) n (%)                     | TOF (N = 181) n (%)         |
| MTX + other csDMARD     | 0 (0%)                           | 2 (0.4%)                                 | 0 (0.0%)                                 | 589 (41.0%)                |
|                         |                                  |                                          |                                          | 146 (39.7%)                |
|                         |                                  |                                          |                                          | 286 (30.9%)                |
|                         |                                  |                                          |                                          | 78 (32.0%)                 |
| MTX only                | 0 (0%)                           | 0 (0%)                                   | 31 (6.7%)                                | 75 (3.9%)                  |
|                         |                                  |                                          |                                          | 556 (38.7%)                |
|                         |                                  |                                          |                                          | 150 (40.8%)                |
|                         |                                  |                                          |                                          | 355 (41.0%)                |
|                         |                                  |                                          |                                          | 79 (32.4%)                 |
| csDMARD (excl. MTX)     | 0 (0%)                           | 24 (5.2%)                                | 7 (3.9%)                                 | 290 (19.6%)                |
|                         |                                  |                                          |                                          | 72 (19.6%)                 |
|                         |                                  |                                          |                                          | 131 (15.1%)                |
|                         |                                  |                                          |                                          | 45 (18.4%)                 |
| bDMARD monotherapy      | 720 (100%)                       | 282 (100%)                               | 406 (87.7%)                             | 167 (92.1%)                |
|                         |                                  |                                          |                                          | 0 (0%)                     |
|                         |                                  |                                          |                                          | 0 (0%)                     |
|                         |                                  |                                          |                                          | 112 (12.9%)                |
|                         |                                  |                                          |                                          | 42 (17.2%)                 |

This is limited to patients who remain on their index b/tsDMARD at the time.